These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9679991)

  • 1. Assessment of the time-tradeoff values for prophylactic mastectomy of women with a suspected genetic predisposition to breast cancer.
    Unic I; Stalmeier PF; Verhoef LC; van Daal WA
    Med Decis Making; 1998; 18(3):268-77. PubMed ID: 9679991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic mastectomy or screening in women suspected to have the BRCA1/2 mutation: a prospective pilot study of women's treatment choices and medical and decision-analytic recommendations.
    Unic I; Verhoef LC; Stalmeier PF; van Daal WA
    Med Decis Making; 2000; 20(3):251-62. PubMed ID: 10929847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers.
    van Roosmalen MS; Stalmeier PF; Verhoef LC; Hoekstra-Weebers JE; Oosterwijk JC; Hoogerbrugge N; Moog U; van Daal WA
    J Clin Oncol; 2004 Aug; 22(16):3293-301. PubMed ID: 15310772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The quality of life associated with prophylactic treatments for women with BRCA1/2 mutations.
    Grann VR; Jacobson JS; Sundararajan V; Albert SM; Troxel AB; Neugut AI
    Cancer J Sci Am; 1999; 5(5):283-92. PubMed ID: 10526669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a shared decision making program for women suspected to have a genetic predisposition to breast cancer: preliminary results.
    Stalmeier PF; Unic IJ; Verhoef LC; Van Daal WA
    Med Decis Making; 1999; 19(3):230-41. PubMed ID: 10424830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
    Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
    J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.
    Kuschel B; Lux MP; Goecke TO; Beckmann MW
    Eur J Cancer Prev; 2000 Jun; 9(3):139-50. PubMed ID: 10954253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decision making regarding prophylactic mastectomy: stability of preferences and the impact of anticipated feelings of regret.
    van Dijk S; van Roosmalen MS; Otten W; Stalmeier PF
    J Clin Oncol; 2008 May; 26(14):2358-63. PubMed ID: 18467728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decision analysis of prophylactic surgery or screening for BRCA1 mutation carriers: a more prominent role for oophorectomy.
    van Roosmalen MS; Verhoef LC; Stalmeier PF; Hoogerbrugge N; van Daal WA
    J Clin Oncol; 2002 Apr; 20(8):2092-100. PubMed ID: 11956270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy.
    Metcalfe KA; Narod SA
    J Natl Cancer Inst; 2002 Oct; 94(20):1564-9. PubMed ID: 12381709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.
    Calderon-Margalit R; Paltiel O
    Int J Cancer; 2004 Nov; 112(3):357-64. PubMed ID: 15382059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.
    Meijers-Heijboer H; Brekelmans CT; Menke-Pluymers M; Seynaeve C; Baalbergen A; Burger C; Crepin E; van den Ouweland AW; van Geel B; Klijn JG
    J Clin Oncol; 2003 May; 21(9):1675-81. PubMed ID: 12721241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
    Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
    Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
    Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
    Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L
    Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic mastectomy and genetic testing: an update.
    Houshmand SL; Campbell CT; Briggs SE; McFadden AW; Al-Tweigeri T
    Oncol Nurs Forum; 2000; 27(10):1537-47; quiz 1548-9. PubMed ID: 11103373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage.
    Kurian AW; Hartman AR; Mills MA; Ford JM; Daniel BL; Plevritis SK
    Health Expect; 2005 Sep; 8(3):221-33. PubMed ID: 16098152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
    Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
    J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients.
    Grann VR; Panageas KS; Whang W; Antman KH; Neugut AI
    J Clin Oncol; 1998 Mar; 16(3):979-85. PubMed ID: 9508180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.